Top

Published in:

01-05-2008 | Original Article

Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines

Authors: Rosa Méndez, Teresa Rodríguez, Ana Del Campo, Eva Monge, Isabel Maleno, Natalia Aptsiauri, Pilar Jiménez, Susana Pedrinaci, Graham Pawelec, Francisco Ruiz-Cabello, Federico Garrido

Published in: Cancer Immunology, Immunotherapy | Issue 5/2008

Abstract

Background

Altered HLA class I cell surface expression is one of the major mechanisms by which tumor cells escape from T lymphocytes. Immunohistochemistry-defined phenotypes of lost HLA class I expression have been described in human solid tumors, nut less information is available on melanoma cell lines.

Objectives

To describe the frequency and distribution of different types of HLA class I antigen alterations in 91 melanoma cell lines from the European Searchable Tumour Cell and Databank (ESTDAB).

Methods

The HLA class I expression was assessed by flow cytometry and HLA genotyping.

Results

We found various types of HLA class I cell surface alterations in about 67% of the melanoma cell lines. These alterations range from total to selective HLA class I loss due to loss of heterozygosity (LOH), haplotype loss, β2-microglobulin gene mutation, and/or total or selective down-regulation of HLA class I molecules. The most frequently observed phenotype is down-regulation of HLA-B locus that was reversible after treatment with IFN -γ.

Conclusions

In general, HLA class I alterations in the majority of the cells analyzed were of regulatory nature and could be restored by IFN-γ. Analysis of the frequency of distinct HLA class I altered phenotypes in these melanoma cell lines revealed specific differences compared to other types of tumors.

Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F (2007) MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 256:139PubMedCrossRef

Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520PubMedCrossRef

Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F (2003) Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 61:211PubMedCrossRef

Cabrera T, Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F (1996) High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50:127PubMedCrossRef

Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52:1PubMed

Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP (1996a) A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 13:210PubMedCrossRef

de Nooij-van Dalen AG, van Buuren-van Seggelen VH, Lohman PH, Giphart-Gassler M (1998) Chromosome loss with concomitant duplication and recombination both contribute most to loss of heterozygosity in vitro. Genes Chromosomes Cancer 21:30PubMedCrossRef

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 11:991–998CrossRef

Fehling HJ, Swat W, Laplace C, Kuhn R, Rajewsky K, Muller U, von Boehmer H (1994) MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 265(5176):1234PubMedCrossRef

10.

Garcia-Loza A, Algarra I, Collado A, Garrido F (2003) Tumour immunology, vaccination and escape strategies. Eur J Immunogenet 30(3):177–183CrossRef

11.

Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117PubMed

12.

Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491PubMedCrossRef

13.

Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F (1995) HLA class I antigens in human tumors. Adv Cancer Res 67:155PubMedCrossRef

14.

Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89PubMedCrossRef

15.

Garrido F, Cabrera T, Acolla RS, Bensa JC, Bodmer W, Dohr G, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades Crh, Salvaneschi L, Stern PL, Ziegler A (1997) HLA and cancer: 12th international histocompatibility workshop study. In: Charron D (ed) HLA, genetic diversity of HLA. Functional and medical implications, vol 1. EDK, Paris, p 445

16.

Gasparollo A, Coral S, Ciullo M, Prisco A, Cattarossi I, Sigalotti L, Altomonte M, Guardiola J, Maio M (2001) Unbalanced expression of HLA-A and –B antigens: a specific feature of cutaneous melanoma and other non-hematopoetic malignancies reverted by IFN-gamma. Int J Cancer 91(4):500PubMedCrossRef

17.

Griffioen M, Ouwerkerk IJ, Harten V, Schrier PI (2000) HLA-B locus-specific downregulation in human melanoma requires enhancer A as well as a sequence element located downstream of the transcription initiation site. Immunogenetics 52:121PubMedCrossRef

18.

Jimenez P, Canton J, Collado A, Cabrera T, Serrano A, Real LM, Garcia A, Ruiz-Cabello F, Garrido F (1999) Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 83:91PubMedCrossRef

19.

Kageshita T, Ishihara T, Campoli M, Ferrone S (2005) Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65:419PubMedCrossRef

20.

Kaklamanis L, Gatter KC, Hill AB, Mortensen N, Harris AL, Krausa P, McMichael A, Bodmer JG, Bodmer WF (1992) Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer 51:379PubMedCrossRef

21.

Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3(11):999–1005PubMedCrossRef

22.

Koene G, Arts-Hilkes Y, van der Ven K, Rozemuller E, Slootweg P, de Weger R, Tilanus M (2004) High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of beta 2-microglobulin LOH analysis. Tissue Antigens 64:452PubMedCrossRef

23.

Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191(6):961PubMedCrossRef

24.

Lopez Nevot MA, Garcia E, Pareja E, Bonal FJ, Martin J, Ruiz-Cabello F, Serrano S, Garrido F (1986) Differential expression of HLA class I and II antigens in primary and metastatic melanomas. J Immunogenet 13:219PubMedCrossRef

25.

Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F (2002) Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51:389PubMedCrossRef

26.

Maleno I, Romero JM, Cabrera T, Paco L, Aptsiauri N, Cozar JM, Tallada M, Lopez-Nevot MA, Garrido F (2006) LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics 58:503PubMedCrossRef

27.

McEvoy CR, Morley AA, Firgaira FA (2003) Evidence for whole chromosome 6 loss and duplication of the remaining chromosome in acute lymphoblastic leukemia. Genes Chromosomes Cancer 37:321PubMedCrossRef

28.

Natali PG, Aguzzi A, Veglia F, Imai K, Burlage RS, Giacomini P, Ferrone S (1983) The impact of monoclonal antibodies on the study of human malignant melanoma. J Cutan Pathol 10:514PubMedCrossRef

29.

Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, Wang LD, Yang CS (2001) DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22:1615PubMedCrossRef

30.

Nikolova P, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, Marinova DI, Ivanova SS, Naumova EJ (2007) Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 56:371PubMedCrossRef

31.

Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, Gloghini A, Striegel S, Schwinn N, Carbone A, Hildenbrand R, Cerwenka A, Maio M, Schadendorf D (2006) The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res 12:3297PubMedCrossRef

32.

Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759PubMedCrossRef

33.

Pawelec G, Koch S, Griesemann H, Rehbein A, Hahnel K, Gouttefangeas C (2006) Immunosenescence, suppression and tumour progression. Cancer Immunol Immunother 55:981PubMedCrossRef

34.

Pawelec G, Marsh S (2006) ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunol Immunother 55:623PubMedCrossRef

35.

Perez B, Benitez R, Fernandez MA, Oliva MR, Soto JL, Serrano S, Lopez Nevot MA, Garrido F (1999) A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 53:569PubMedCrossRef

36.

Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F (2000) Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 61:1001PubMedCrossRef

37.

Rodriguez T, Mendez R, Del Campo A, Jimenez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34PubMedCrossRef

38.

Rodriguez T, Mendez R, Roberts CH, Ruiz-Cabello F, Dodi IA, Lopez Nevot MA, Paco L, Maleno I, Marsh SG, Pawelec G, Garrido F (2005) High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother 54:141PubMedCrossRef

39.

Romero JM, Jimenez P, Cabrera T, Cozar JM, Pedrinaci S, Tallada M, Garrido F, Ruiz-Cabello F (2005) Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 113:605PubMedCrossRef

40.

Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van ’t Veer LJ, Kruse-Wolters KM (1991) Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Semin Cancer Biol 2:73PubMed

41.

Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 94:243PubMedCrossRef

42.

Soong TW, Hui KM (1992) Locus-specific transcriptional control of HLA genes. J Immunol 149:2008PubMed

43.

Versteeg R, Kruse-Wolters KM, Plomp AC, van Leeuwen A, Stam NJ, Ploegh HL, Ruiter DJ, Schrier PI (1989) Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J Exp Med 170:621PubMedCrossRef

44.

Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715PubMedCrossRef

Title: Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines
Authors: Rosa Méndez
Teresa Rodríguez
Ana Del Campo
Eva Monge
Isabel Maleno
Natalia Aptsiauri
Pilar Jiménez
Susana Pedrinaci
Graham Pawelec
Francisco Ruiz-Cabello
Federico Garrido
Publication date: 01-05-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 5/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0411-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2008

Clinical impact of HLA class I expression in rectal cancer

Acknowledgement

Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model

MYCN as a target for cancer immunotherapy

Migration deficit in monocyte-macrophages in human ovarian cancer

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer